梅奧診所綜合癌癥中心的研究人員已經(jīng)確定了一種基因標(biāo)志物,該基因標(biāo)記可能導(dǎo)致更有效,更精確的胰腺癌(PDAC)治療。相關(guān)研究結(jié)果于近日發(fā)表在《Nature Cancer》上,題為“METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma.”